Table of Contents
- 1 What is Minimal Residual Disease (MRD)?
- 2 What role does Minimal Residual Disease (MRD) assessment play in-patient care?
- 3 Is a negative MRD result a positive sign?
- 4 How does MRD testing affect my treatment?
- 5 When would doctors test for MRD?
- 6 What are the techniques used to detect MRD?
- 7 MRD Testing in Specific Blood Cancers
- 8 FAQs
What is Minimal Residual Disease (MRD)?

After treatment, there may be a small number of cancer cells that remain in the body. This is referred to as minimal residual disease (MRD). The remaining number of cells may be so small that they do not cause any physical signs or symptoms..
They usually go undetected through traditional methods, such as viewing cells under a microscope or by checking for abnormal serum proteins in the blood. If a patient receives a MRD positive test result, it means that residual (remaining) cancer cells have been detected. A negative result means that no residual disease is detected.
.
What role does Minimal Residual Disease (MRD) assessment play in-patient care?

Any remaining cancer cells can become active and begin to multiply, causing the patient to relapse. MRD assessment helps indicate if the treatment was not completely effective. Minimal residual disease might be present after treatment because not all the cancer cells responded to therapy.
.
Is a negative MRD result a positive sign?

A positive test result for MRD, known as “MRD positivity”, indicates that residual cancer cells are present in the body after treatment. When a patient tests negative for minimal residual disease, known as “MRD negativity”, there are no remaining cancer cells..
Being “MRD negative” is an encouraging outcome for a patient with blood cancer. MRD negativity means that even with advanced, sensitive tests, no cancer cells were detected. According to studies, MRD negativity is associated with longer remissions and potentially longer rates of survival for certain blood cancers.
.
How does MRD testing affect my treatment?

Testing for MRD can help our treatment team distinguish between patients who need additional or different treatment from those who do not. This knowledge can also guide treatment decisions and improve patient outcomes..
Minimal residual disease testing helps:
- Show how well cancer has responded to treatment
- Confirm and monitor remissions
- Detect cancer recurrence sooner than other tests
- Identify a higher risk of relapse in patients
- Identify the need to restart treatment
- Identify patients who are candidates for procedures such as stem cell transplantation or combination therapy.
.
When would doctors test for MRD?

Testing for MRD in patients is dependent on varying factors specific to the patient’s disease..
Patients may be tested:
- After bone marrow transplantation.
- After the last cycle of a planned combination therapy.
- During treatment.
- After one year of maintenance therapy.
- To confirm the depth of remission.
- At regular intervals, once treatment is completed.
- At other specific times.
.
What are the techniques used to detect MRD?

MRD testing uses highly sensitive methods such as flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). Each of these tests uses bone marrow cell samples taken through aspiration, or peripheral blood cells taken through a vein.
.
.
MRD Testing in Specific Blood Cancers

The type of MRD testing used depends on the type of blood cancer.
.
.
.
.
.
.
FAQs

Depending on the condition, restarting treatment again such as chemotherapy, radiotherapy or immunotherapy may be required. After detecting minimal residual disease, some patients may be candidates for stem cell transplantation or combination therapy.
While 80-90% of children and young adults will respond to initial ALL treatment, it is estimated that approximately 10-15% will experience disease relapse. For adults, the risk of disease relapse is even higher at 40-50%.
While high-grade Lymphomas tend to progress more rapidly, a good proportion of high-grade Lymphomas can be effectively treated with a low risk of relapse.
Low-grade Lymphomas often respond well to treatments available. However, they are not usually cured and may recur eventually over time.
Acute myeloid leukaemia is an aggressive and fast-growing cancer. A patient’s outcome depends on the type of AML they are diagnosed with, their individual health, and recommended treatment plan.
While many cases of AML can be cured with treatment such as chemotherapy or a bone marrow transplant, the outcomes still depend on the patient’s age and fitness, as well as the AML risk groups.
For patients with standard risk AML, approximately 50% of patients may be successfully treated with existing treatments. For patients with favourable risk AML, approximately 60-70% of patients may have a durable remission. However, for patients with poor risk AML, the chances of a durable remission are less than 25%.
While there is, unfortunately, no cure for multiple myeloma currently, treatment such as chemotherapy and immunotherapy, amongst others, can be used to successfully manage the condition for years.
With the introduction of novel drug therapies, as well as the use of 3-4 drug combinations for upfront treatment of myeloma, the majority of newly diagnosed myeloma patients are able to achieve a partial or complete response to initial therapy.
Many of these patients will eventually relapse over time. Treatment strategies such as the use of autologous stem cell transplantation, as well as the use of longer term maintenance therapy have been adopted successfully to delay the time to relapse (ie. prolong the disease free interval)
These approaches do not factor in variables such as age and overall health. Speak to our doctor for a better understanding of the success rates of your treatment plan.
Related Links
Related Links
Locations
Contact
WhatsApp : +65 6256 8836
Email : contact@cfch.com.sg
.
Consultation Hours
Monday to Friday : 8.30am – 5.30pm
Saturday : 8.30am – 12.30pm
Closed on Sunday & Public Holidays
Find us On Facebook
Drop a Line
Disclaimer | 2023 Centre For Clinical Haematology
Website Created by Cleveraa
Locations
Contact
WhatsApp : +65 6256 8836
Email : contact@cfch.com.sg
.
Consultation Hours
Monday to Friday : 8.30am – 5.30pm
Saturday : 8.30am – 12.30pm
Closed on Sunday & Public Holidays
Find us on Facebook
Drop a Line
Disclaimer | 2023 Centre For Clinical Haematology | Website Created by Cleveraa